Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prenetics Global Limited filings document a foreign private issuer that furnishes Form 6-K reports for material corporate updates, financial results and press-release exhibits. The filings cover the company’s IM8 consumer health and longevity business, including product and partnership announcements, operating results, registration-statement incorporation and disclosures tied to its focus on global expansion of the brand.
The filing record also documents capital allocation and governance matters, including Class A Ordinary Share repurchase authorization, executive open-market share purchases, board changes, treasury policy related to digital assets and completed divestiture activity such as the sale of the company’s Insighta equity interest. These disclosures frame Prenetics’ capital structure, liquidity commentary and reported business priorities as a public foreign issuer.
Prenetics Global Limited reported record 2025 results driven by its IM8 consumer health brand. Full-year revenue jumped to $92.4 million, up 479.7% year over year, with fourth-quarter revenue at $36.6 million, a 457.1% increase, as IM8 became the main growth engine.
IM8 delivered $60.1 million of 2025 revenue and reached about $120 million in annualized recurring revenue by December 2025, with December monthly revenue at $10.0 million and gross margin near 60%. Company-wide adjusted EBITDA loss narrowed to $13.0 million for 2025 and $2.3 million in Q4, showing improving operating leverage despite heavy marketing spend.
Prenetics completed divestitures of ACT Genomics, Europa and its 35% Insighta stake, lifting total adjusted liquidity to $171.1 million as of February 15, 2026, with no debt. Management reaffirmed 2026 IM8 revenue guidance of $180–$200 million and outlined a path toward adjusted EBITDA profitability by the fourth quarter of 2027.
Prenetics Global Limited reported record 2025 results driven by its IM8 consumer health brand. Full-year revenue jumped to $92.4 million, up 479.7% year over year, with fourth-quarter revenue at $36.6 million, a 457.1% increase, as IM8 became the main growth engine.
IM8 delivered $60.1 million of 2025 revenue and reached about $120 million in annualized recurring revenue by December 2025, with December monthly revenue at $10.0 million and gross margin near 60%. Company-wide adjusted EBITDA loss narrowed to $13.0 million for 2025 and $2.3 million in Q4, showing improving operating leverage despite heavy marketing spend.
Prenetics completed divestitures of ACT Genomics, Europa and its 35% Insighta stake, lifting total adjusted liquidity to $171.1 million as of February 15, 2026, with no debt. Management reaffirmed 2026 IM8 revenue guidance of $180–$200 million and outlined a path toward adjusted EBITDA profitability by the fourth quarter of 2027.
Prenetics Global Limited reports a Board change and a sharpened strategic focus on its IM8 health and longevity brand. Director Andy Cheung resigned effective February 16, 2026, with the company stating his departure was not due to any disagreement. As part of its renewed focus, Prenetics has discontinued any future purchases of Bitcoin or other cryptocurrencies effective December 4, 2025.
The company appointed Dr. Darshan Shah, a longevity expert and health-tech CEO, as an independent director effective February 16, 2026, and he will also serve on key Board committees. Prenetics highlights IM8’s rapid growth, noting the brand surpassed $100 million in annualized recurring revenue within 11 months and is now sold in more than 30 countries.
Prenetics Global Limited reports a Board change and a sharpened strategic focus on its IM8 health and longevity brand. Director Andy Cheung resigned effective February 16, 2026, with the company stating his departure was not due to any disagreement. As part of its renewed focus, Prenetics has discontinued any future purchases of Bitcoin or other cryptocurrencies effective December 4, 2025.
The company appointed Dr. Darshan Shah, a longevity expert and health-tech CEO, as an independent director effective February 16, 2026, and he will also serve on key Board committees. Prenetics highlights IM8’s rapid growth, noting the brand surpassed $100 million in annualized recurring revenue within 11 months and is now sold in more than 30 countries.
Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for total cash proceeds of $70 million, providing a substantial, non‑dilutive cash inflow and strengthening its balance sheet.
As of February 15, 2026, Prenetics reported total adjusted liquidity of $171.1 million, including $99.3 million in cash and cash equivalents, $29.3 million in financial assets at fair value through profit or loss, $7.3 million in escrow balances and $35.2 million in Bitcoin, while operating with zero outstanding debt. Management frames this divestiture as the final major step in a strategic shift to focus on IM8, its fast‑growing consumer health and longevity brand, supporting global expansion and product innovation. The company plans to discuss its financial position and outlook with fourth‑quarter and full‑year 2025 results, scheduled for pre‑market release on February 18, 2026.
Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for total cash proceeds of $70 million, providing a substantial, non‑dilutive cash inflow and strengthening its balance sheet.
As of February 15, 2026, Prenetics reported total adjusted liquidity of $171.1 million, including $99.3 million in cash and cash equivalents, $29.3 million in financial assets at fair value through profit or loss, $7.3 million in escrow balances and $35.2 million in Bitcoin, while operating with zero outstanding debt. Management frames this divestiture as the final major step in a strategic shift to focus on IM8, its fast‑growing consumer health and longevity brand, supporting global expansion and product innovation. The company plans to discuss its financial position and outlook with fourth‑quarter and full‑year 2025 results, scheduled for pre‑market release on February 18, 2026.
Prenetics Global Limited submitted a report describing a recent corporate update. On December 30, 2025, the company issued a press release announcing an update to its capital allocation strategy and the cessation of Bitcoin purchases. The report states that this press release is included as an exhibit and is being incorporated by reference into several existing Form F-3 and Form S-8 registration statements, allowing those registration documents to reflect the latest information about the company’s capital allocation approach.
Prenetics Global Limited reports that it will hold its 2025 annual general meeting of shareholders on December 19, 2025. The notice of annual general meeting is furnished as Exhibit 99.1 to this report.
The company also states that this report is incorporated by reference into its existing registration statements on Form F-3 (File Nos. 333-274762, 333-276538 and 333-288824) and Form S-8 (File Nos. 333-279019, 333-271552 and 333-267956), so the information becomes part of those registration statement disclosures.
Prenetics Global Limited submitted a Form 6-K as a foreign private issuer for November 2025. The company reports that on November 24, 2025 it issued a press release announcing open market purchases of its shares by several members of its executive leadership team. The press release describing these executive share purchases is furnished as Exhibit 99.1 to the report.
Prenetics Global Limited reported that its Chief Executive Officer and co‑founder, Danny Sheng Wu Yeung, bought additional shares of the company in the open market. On November 19, 2025, he purchased 20,000 Class A Ordinary Shares at $13.00 per share, for a total purchase price of $260,000. Following this transaction, his total holdings of Class A Ordinary Shares increased to 96,412 shares. This reflects a personal capital commitment by the CEO using his own funds rather than an issuance of new shares by the company.
Prenetics Global Limited (PRE) reported that its Chief Executive Officer and co-founder, Danny Sheng Wu Yeung, bought additional company stock on the open market. On November 18, 2025, he purchased 20,118 Class A Ordinary Shares at a price of $12.02 per share, for a total of about $242,000. Following this transaction, his holdings in the company’s Class A Ordinary Shares increased to 76,412, signaling a higher personal stake in Prenetics’ future performance.
Prenetics Global Limited reported that its Chief Marketing Officer, Rahul Ramchand, bought 30,000 Class A ordinary shares on the open market on November 14, 2025. He paid $13.29 per share, for a total purchase price of $398,821. Following this transaction, his total holdings increased to 75,553 Class A ordinary shares of the company. This filing simply records the executive share purchase and resulting ownership level.
Prenetics Global Limited reported that its Chief Marketing Officer, Rahul Ramchand, purchased 30,000 Class A Ordinary Shares in the open market on November 12, 2025 at $13.17 per share, for a total of $395,151. Following this transaction, his holdings increased to 45,553 Class A Ordinary Shares.
The purchase was disclosed via a Form 6-K and reflects an executive open-market buy.